425: PowerUp Acquisition Corp. Amends Merger Agreement with Aspire Biopharma, Adjusting Merger Consideration and Equity Incentive Plan

PowerUp Acquisition Corp. and Aspire Biopharma amend their merger agreement to adjust the merger consideration, equity incentive plan size, and extend the disclosure schedule delivery date.

Summary

• PowerUp Acquisition Corp. and Aspire Biopharma have amended their merger agreement, initially signed on August 26, 2024.
• The amendment, dated September 5, 2024, adjusts the merger consideration to align with the anticipated post-closing ownership percentage of Aspire stockholders.
• It also adjusts the size of the equity incentive plan for the initial fiscal year after closing.
• The parties have extended the deadline for delivering disclosure schedules to September 18, 2024, to allow for additional due diligence.
• Failure to cure any items set forth in Disclosure Issue Notice shall allow the non-disclosing Party to terminate this Agreement pursuant to Section 7.1(i).
• The merger consideration is now defined as $350,000,000, less any shortfall in Aspire's cash at closing compared to the Minimum Cash Condition (if waived by Purchaser), and less Company Indebtedness at Closing.
• The equity incentive plan will reserve shares equal to the greater of 10% of the Purchaser Common Stock to be issued and outstanding immediately after the Closing and 5,000,000 shares of Purchaser Common Stock, and shall include an evergreen provision that will provide for an automatic increase on the first day of each fiscal year in the number of shares available for issuance under the Purchaser Equity Incentive Plan such that the total number of shares available for issuance under the Purchaser Equity Incentive Plan is equal to ten percent (10%) of the total number of shares of Purchaser Common Stock then-issued and outstanding as of the last day of the prior fiscal year or such lesser amount as determined by the compensation committee of the Purchaser.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the document announces an amendment to a merger agreement, which could be seen as positive, it also includes extensive risk disclosures, balancing the overall tone.

Positives

• The amendment aligns the merger consideration and equity incentive plan with the original intentions of the parties.
• The extension of the disclosure schedule delivery date allows for more thorough due diligence.
• The equity incentive plan includes an evergreen provision, ensuring continued alignment of incentives.

Risks

• The announcement includes a comprehensive list of risk factors associated with the business combination, including potential failure to complete the merger, redemptions exceeding anticipated levels, and failure to meet Nasdaq listing standards.
• Aspire may not be able to execute its growth strategies or develop and maintain effective internal controls.
• There are risks related to supply chain disruptions, product liability lawsuits, and intellectual property protection.
• Aspire may need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.

Future Outlook

The document contains forward-looking statements regarding the anticipated benefits and timing of the proposed business combination, as well as the future financial condition and performance of Aspire and the combined company; however, these statements are subject to numerous risks and uncertainties.

Industry Context

This announcement is typical of SPAC transactions, where initial agreements are often refined through amendments as due diligence progresses. The adjustments to merger consideration and equity incentive plans are common in such deals to ensure alignment between parties.

Comparison to Industry Standards

• SPAC mergers often involve adjustments to deal terms during the due diligence phase, reflecting the dynamic nature of these transactions.
• Comparable companies in the biopharma sector often use equity incentive plans to attract and retain talent, with the size of the plan typically ranging from 5% to 15% of outstanding shares.
• The $350 million merger consideration is within the typical range for biopharma companies of Aspire's size and stage of development.

Stakeholder Impact

• Shareholders of PowerUp will be impacted by the proposed business combination and will vote on the agreement.
• Aspire's business relationships and operating results could be affected by the announcement and pendency of the proposed business combination.
• Employees of both PowerUp and Aspire may be affected by the integration of the two companies.

Next Steps

• PowerUp will file relevant materials with the SEC, including a registration statement on Form S-4.
• Shareholders of PowerUp will vote on the proposed business combination.
• The parties will work to satisfy the closing conditions outlined in the Business Combination Agreement.

Key Dates